Projects per year
Abstract
Background Exploitation of the sodium iodide symporter (NIS) has potentially broad clinical application across different tumour ablative settings but often fails in aggressive cancer due to diminished transport activity. We aimed to discover whether enhancing NIS function by modulating proteostasis was targetable in vivo, as well as the clinical relevance to radioiodide (RAI) treatment of patients with cancer.
Methods We used 3D modelling, iterative design, reformulation, RAI uptake, RNA-Seq, cell surface biotinylations assays and NanoBRET in transformed cell lines and primary thyroid cells from patients to identify new drugs targeted at enhancing NIS function and to uncover their respective mechanisms. Systemic drug responses were monitored via 99mTc pertechnetate gamma counting and SPECT/CT imaging in wild-type BALB/c and Tg-rtTA/tetO-BRAFV600E mice, as well as orthotopic NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) breast cancer.
Findings In this study, we discovered that copper diethyldithiocarbamate (Cu(DDC)2), a metabolite of the FDA-approved drug disulfiram, modulated NIS function in thyroid and breast cancer cells (p < 0.05). Mechanistically, Cu(DDC)2 elicited a dual effect on NIS function, targeting valosin containing protein (VCP) – a key regulator of proteostasis – as well as inducing potent transcriptional responses (p < 0.05). In mice, the copper-bound metabolite stimulated NIS activity in normal thyroid tissue, thyroid tumours and in breast orthotopic tumours (p < 0.05), the latter augmented by the histone deacetylase inhibitor vorinostat (SAHA). Notably, there was clinical association of drug-perturbed genes in RAI-treated thyroid cancer, enabling construction of a robust dual risk score classifier for predicting recurrence (AUC > 0.95; p < 0.001).
Interpretation Our findings reveal a new mechanistic pathway towards enhancing radionuclide uptake in vivo, with clinical relevance for RAI therapy and identifying survival indicators of recurrent disease.
Methods We used 3D modelling, iterative design, reformulation, RAI uptake, RNA-Seq, cell surface biotinylations assays and NanoBRET in transformed cell lines and primary thyroid cells from patients to identify new drugs targeted at enhancing NIS function and to uncover their respective mechanisms. Systemic drug responses were monitored via 99mTc pertechnetate gamma counting and SPECT/CT imaging in wild-type BALB/c and Tg-rtTA/tetO-BRAFV600E mice, as well as orthotopic NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) breast cancer.
Findings In this study, we discovered that copper diethyldithiocarbamate (Cu(DDC)2), a metabolite of the FDA-approved drug disulfiram, modulated NIS function in thyroid and breast cancer cells (p < 0.05). Mechanistically, Cu(DDC)2 elicited a dual effect on NIS function, targeting valosin containing protein (VCP) – a key regulator of proteostasis – as well as inducing potent transcriptional responses (p < 0.05). In mice, the copper-bound metabolite stimulated NIS activity in normal thyroid tissue, thyroid tumours and in breast orthotopic tumours (p < 0.05), the latter augmented by the histone deacetylase inhibitor vorinostat (SAHA). Notably, there was clinical association of drug-perturbed genes in RAI-treated thyroid cancer, enabling construction of a robust dual risk score classifier for predicting recurrence (AUC > 0.95; p < 0.001).
Interpretation Our findings reveal a new mechanistic pathway towards enhancing radionuclide uptake in vivo, with clinical relevance for RAI therapy and identifying survival indicators of recurrent disease.
| Original language | English |
|---|---|
| Article number | EBIOM_106165 |
| Journal | EBioMedicine |
| Publication status | Accepted/In press - 26 Jan 2026 |
Bibliographical note
Not yet published as of 02/02/2026Fingerprint
Dive into the research topics of 'Disulfiram metabolite Cu(DDC)2 enhances radionuclide uptake in vivo revealing insights into tumoural ablation resistance'. Together they form a unique fingerprint.-
TRANSFORMING CELLULAR IMAGING AND ABLATION STRATEGIES VIA NEW MECHANISTIC UNDERSTANDING OF THE SODIUM IODIDE SYMPORTER
McCabe, C. (Principal Investigator)
1/12/24 → 31/05/28
Project: Research Councils
-
Making Radioiodine Treatment a Realistic Therapeutic Opportunity in Breast Cancer
McCabe, C. (Principal Investigator)
30/09/21 → 29/09/25
Project: Research
-
Can new drug approaches elicit a novel dual action of radioiodine treatment?
McCabe, C. (Principal Investigator)
1/09/21 → 31/05/24
Project: Research
-
MRC CiC New clotrimazole analogues to improve radioiodine treatment of thyroid cancer
McCabe, C. (Principal Investigator), Cox, L. (Co-Investigator) & Bottegoni, G. (Researcher)
1/06/21 → 31/03/23
Project: Research Councils